Overview
Lindsey Dimond advises on international arbitration, commercial litigation, investor-state arbitrations, civil fraud, and enforcement matters. Her work focuses on high-value, complex, cross-border disputes and frequently involves the coordination of multiple proceedings, arbitrations and investigations in a number of jurisdictions.
Lindsey has experience with arbitrations arising under the rules of, among others, International Chamber of Commerce (ICC), the London Court of International Arbitration (LCIA), International Chamber of Commerce (ICC), and International Centre for Settlement of Investment Disputes (ICSID). Her clients include multi-national corporations, banks, and ultra-high-net-worth individuals.
- New York State Bar
- LL.M., Queen Mary University of London
- LL.B., University of Cape Town
- B.Soc.Sci., University of Cape Town, Philosophy
Representative Matters
- Acts as counsel to US investors in respect of a legacy investment claim brought against Canada under the transitional provisions of the US-Mexico Canada Agreement. The case arises out of the arbitrary and discriminatory treatment of a US investor in connection with the proposed construction of a carbon-neutral LNG facility in Québec and of a natural gas pipeline connecting Northern Ontario and Québec. Ruby River Capital LLC v. Canada. ICSID arbitration.
- Acts as counsel to US investors in respect of a NAFTA arbitration against Canada. The case concerns the summary termination of Ontario's greenhouse gas emissions control cap-and-trade program without payment of compensation to our clients. Koch Industries, Inc. and Koch Supply & Trading, LP v. Canada. ICSID arbitration.
- Acts as counsel to the investors in an ICSID arbitration relating to the expropriation of a substantial aquaculture enterprise by The Gambia. West African Aquaculture Ltd et al. v. The Republic of The Gambia. ICSID arbitration.
- Acted for a multi-national pharmaceutical company in a successful US$2.44 billion M&A dispute arising from the acquisition of a European over-the-counter pharmaceutical company.
- Acted for a software developer in relation to a £500 million claim by the UK Government.
News & Publications
Press Releases
April 5, 2024